 |
|
|
|
|
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Roses A. on PAPER: Chu SH. et al., 2011, When we first saw this paper published, we noted that one of the PCR primers was identical to... 25 Jul 2012.
|
|
|
 |
|
|
Roses A. on NEWS: Mitochondria Stumble Their Way Along Axons in ALS Model, Recommendation Only. 9 Jan 2012.
|
|
|
|
|
|
Roses A. on PAPER: Sperling RA. et al., 2011, The assumptions are that amyloid deposition is the instigating event and thus the right target,... 7 Dec 2011.
|
|
|
|
|
|
Roses A. on PAPER: Cruchaga C. et al., 2011, It is positive that Cruchaga et al. support the association between the poly-T repeat (“523”)... 15 Aug 2011.
|
|
|
|
|
|
Roses A. on PAPER: Chiang GC. et al., 2010, It is not surprising at all that there is a difference in the "hippocampal atrophy rates and... 9 Nov 2010.
|
|
|
|
|
|
Roses A. on NEWS: Abnormal Mitochondrial Dynamics—Early Event in AD, PD?, For mitochondrial effects in AD please see our 11 Feb 2010.
|
|
|
|
|
|
Roses A. on SITE POLL: What method will be routinely used to predict AD risk?, A variable-length polymorphism in the gene TOMM40 predicts the age of late-onset Alzheimer... 14 Jan 2010.
|
|
|
|
|
|
Roses A. on SITE POLL: Would you get tested for your ApoE genotype?, I would choose “other.”
All of the attempted estimates being marketed on the Web are for a... 7 Dec 2009.
|
|
|
|
|
|
Roses A. on NEWS: The A2M Deletion, Revisited, Response from Allen Roses et al. to Tanzi Comment
Below please find a short, absolute... 6 May 1999.
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
Check out our upcoming Webinar: 
